Dir
Ellen R. Strahlman, MD, MS is an Independent Board Member (Director) at Hyperion DeFi, Inc. (NASDAQ: HYPD), bringing extensive C-suite executive experience from global healthcare companies.[[1]](https://ir.hyperiondefi.com/governance/board-of-directors)[[4]](https://www.altria.com/en/about-altria/corporate-governance/board-of-directors/ellen-strahlman) She recently engaged in insider trading activity, including purchasing 38,444 shares worth $120,663 on December 18, 2025,[[2]](https://www.investing.com/news/insider-trading-news/strahlman-buys-hyperion-defi-hypd-shares-worth-120663-93CH-4419372) acquiring an additional 12,112 shares for $43,603 on December 29, 2025,[[6]](https://www.moomoo.com/news/post/63470321/insider-purchase-director-at-hypd-buys-12112-shares) and receiving 50,000 restricted stock units (RSUs) on August 18, 2025, vesting in tranches through 2026.[[3]](https://www.stocktitan.net/sec-filings/HYPD/form-4-hyperion-de-fi-inc-insider-trading-activity-6f8e4bcee479.html)
Dr. Strahlman has held senior leadership roles such as Executive Vice President of Research & Development and Chief Medical Officer at Becton, Dickinson and Company (2013-2018),[[1]](https://ir.hyperiondefi.com/governance/board-of-directors) Senior Vice President and Chief Medical Officer at GlaxoSmithKline (2008-2013),[[1]](https://ir.hyperiondefi.com/governance/board-of-directors) and positions at Pfizer, Novartis, Bausch & Lomb, and Merck.[[1]](https://ir.hyperiondefi.com/governance/board-of-directors) She currently serves on the board of Altria Group, Inc.,[[1]](https://ir.hyperiondefi.com/governance/board-of-directors)[[4]](https://www.altria.com/en/about-altria/corporate-governance/board-of-directors/ellen-strahlman) previously directed Syncona Limited (2016-2020),[[1]](https://ir.hyperiondefi.com/governance/board-of-directors)[[4]](https://www.altria.com/en/about-altria/corporate-governance/board-of-directors/ellen-strahlman) and is a Visiting Professor at the University of Turku.[[1]](https://ir.hyperiondefi.com/governance/board-of-directors) Education includes a BA in biochemistry from Harvard University, MD from Johns Hopkins School of Medicine, ophthalmology training at Wilmer Eye Institute, and MHSc in Epidemiology from Bloomberg School of Public Health.[[1]](https://ir.hyperiondefi.com/governance/board-of-directors)
View full insider profile →
